MannKind's Bear Thesis Remains Intact As Woes Continue

The company continues to dilute shareholder value by taking on enormous amounts of debt, and seems desperate to find ways to fund operations. The recent shake-up among the executive team has replaced ex-CEO Edstrom with former Insulet CEO Duane DeSisto, who possesses a less-than-stellar track record.

from Biotech News